Last updated: July 31, 2026
Ibuprofen and famotidine is marketed in the United States as Duexis, a fixed-dose prescription tablet containing ibuprofen 800 mg and famotidine 26.6 mg. The product is approved for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and for reducing the risk of upper gastrointestinal ulcers in patients requiring chronic ibuprofen therapy.[1] Its commercial value depends on adherence to prescription NSAID therapy, payer coverage, generic competition, and the extent to which prescribers use co-formulated gastroprotection rather than separate NSAID and acid-suppression products.
The clinical evidence supports ulcer-risk reduction, but the product has not established a broad cardiovascular or gastrointestinal safety advantage over appropriate NSAID selection combined with separate gastroprotection. No major new clinical development program has materially changed the product’s regulatory or commercial profile.
What is ibuprofen and famotidine approved to treat?
Duexis combines high-dose ibuprofen with famotidine in a single delayed-release tablet. Each tablet contains:
| Attribute |
Duexis |
| Active ingredients |
Ibuprofen 800 mg and famotidine 26.6 mg |
| FDA application |
NDA 022519 |
| Approval date |
April 28, 2011 |
| Indications |
Osteoarthritis, rheumatoid arthritis, and reduction of upper gastrointestinal ulcer risk |
| Administration |
One tablet three times daily |
| Maximum daily dose |
Ibuprofen 2,400 mg and famotidine 79.8 mg |
| Sponsor at approval |
Horizon Pharma, following development by Pozen |
| Drug class |
NSAID plus histamine-2 receptor antagonist |
| Dosage form |
Delayed-release tablet |
The product is intended for patients who need the ibuprofen dose and may benefit from continuous acid suppression. It is not approved as a general-purpose over-the-counter analgesic or as a treatment for established peptic ulcer disease.[1]
The formulation uses separate-release characteristics to deliver ibuprofen for analgesia and famotidine for gastric acid suppression. The label warns about NSAID-related gastrointestinal bleeding, myocardial infarction, stroke, renal toxicity, hypertension, heart failure, and serious skin reactions. Famotidine does not eliminate the systemic cardiovascular and renal risks of ibuprofen.[1]
What clinical trials support ibuprofen and famotidine?
The principal clinical evidence came from the REDUCE program, which evaluated whether a fixed combination of ibuprofen and famotidine reduced endoscopic gastric and duodenal ulcers compared with ibuprofen alone.
REDUCE-1 and REDUCE-2 trial results
The registration studies enrolled patients with osteoarthritis or rheumatoid arthritis who required chronic NSAID treatment and had risk factors for ulcer development. Patients received either ibuprofen/famotidine or ibuprofen with placebo. The primary endpoint was endoscopically detected gastric or duodenal ulceration during treatment.
| Trial |
Population |
Comparator |
Main finding |
| REDUCE-1 |
Chronic NSAID users with osteoarthritis or rheumatoid arthritis |
Ibuprofen alone |
Lower rate of endoscopic ulcers with ibuprofen/famotidine |
| REDUCE-2 |
Chronic NSAID users with osteoarthritis or rheumatoid arthritis |
Ibuprofen alone |
Confirmed reduction in endoscopic gastric and duodenal ulcers |
Across the pivotal studies, the fixed combination reduced endoscopic ulcers relative to ibuprofen monotherapy. The trials were designed to measure mucosal ulcer formation, not a reduction in gastrointestinal bleeding, perforation, hospitalization, cardiovascular events, or mortality.[1,2]
That distinction limits the scope of the clinical claim. Endoscopic ulcer reduction is a recognized regulatory endpoint for gastroprotection, but it does not demonstrate that the product prevents all clinically important NSAID complications.
What recent clinical trials are evaluating the product?
No major late-stage trial program has been publicly associated with new indications, a new strength, or a new route of administration for ibuprofen/famotidine. ClinicalTrials.gov contains historical studies related to the combination and its ulcer-prevention strategy, but the product’s development status is commercial rather than pipeline-driven.[3]
The most relevant ongoing evidence questions are comparative:
- Whether fixed-dose ibuprofen/famotidine improves adherence compared with separate ibuprofen and proton-pump inhibitor therapy.
- Whether famotidine provides comparable protection to standard-dose proton-pump inhibitors in high-risk NSAID users.
- Whether the product reduces clinically significant gastrointestinal events rather than only endoscopic ulcers.
- Whether chronic exposure at ibuprofen 2,400 mg per day creates an unfavorable cardiovascular risk profile in older or high-risk patients.
These questions have greater clinical relevance than another short-duration endoscopy study. No definitive outcomes trial has established superiority over a proton-pump inhibitor-based gastroprotection regimen.
What is the FDA regulatory status of Duexis?
Duexis is FDA-approved under NDA 022519. Its approval covers chronic symptomatic treatment of osteoarthritis and rheumatoid arthritis in patients who also require reduction of upper gastrointestinal ulcer risk.[1]
The FDA label includes boxed warnings for serious cardiovascular and gastrointestinal events associated with non-aspirin NSAIDs. The drug is contraindicated in the setting of perioperative coronary artery bypass graft surgery, prior serious hypersensitivity to ibuprofen or aspirin-related products, and other conditions specified in the prescribing information.[1]
Is ibuprofen and famotidine available over the counter?
The prescription fixed-dose product is not the same as over-the-counter products that combine ibuprofen with acetaminophen. OTC famotidine products are sold separately, but consumers cannot replicate the Duexis regimen precisely through a single approved OTC product.
The commercial distinction matters because prescription Duexis carries a high ibuprofen dose of 800 mg per tablet. Over-the-counter ibuprofen products generally contain 200 mg per tablet and are labeled for lower self-care dosing.
What patents protect ibuprofen and famotidine?
The original composition-of-matter protection for ibuprofen and famotidine has expired or is no longer the principal commercial barrier. The remaining intellectual-property value has historically depended on formulation, dosage regimen, and methods of reducing NSAID-associated gastrointestinal injury.
| IP category |
Commercial relevance |
| Ibuprofen compound patents |
Expired |
| Famotidine compound patents |
Expired |
| Fixed-dose combination |
Historically important, but vulnerable to invalidity and design-around arguments |
| Delayed-release formulation |
Core protection for the commercial tablet |
| Method-of-use claims |
Directed to reducing ulcers while treating arthritis with high-dose ibuprofen |
| Manufacturing process |
May create practical barriers but generally does not prevent an alternative formulation |
| Brand and trade dress |
Supports market recognition but does not block equivalent products |
The relevant patent estate should be assessed through the FDA Orange Book, USPTO records, and litigation dockets rather than by relying only on the brand label. Orange Book listings can change through patent expiry, delisting, pediatric exclusivity, or court decisions.[4]
What is the Orange Book status of Duexis?
Duexis has been listed in the Orange Book with patents covering the product’s formulation and method of use. The exact blocking effect depends on the status of each listed patent, the applicant’s Paragraph IV certification, and any subsequent court ruling or settlement.[4]
For generic applicants, the key question is whether a proposed product can avoid the listed claims through:
- A different release profile.
- Separate co-packaged tablets instead of a single fixed-dose tablet.
- A different famotidine strength.
- A different dosage schedule.
- A Paragraph III certification accepting patent expiry.
- A Paragraph IV certification alleging invalidity, unenforceability, or non-infringement.
Because both active ingredients are old and inexpensive, formulation and regulatory strategy are more important than active-ingredient supply.
When does ibuprofen and famotidine lose exclusivity?
The product’s original five-year new chemical entity exclusivity did not apply in the same way as it would to a new active ingredient because both ibuprofen and famotidine were previously approved compounds. The commercial exclusivity period therefore depended heavily on formulation patents, method-of-use patents, regulatory exclusivity, and litigation outcomes.
The FDA approval date was April 28, 2011. The statutory five-year NCE period was not the primary barrier to generic entry. Any meaningful protection after approval came from listed patents and related litigation.[1,4]
A generic applicant could seek approval after the relevant Orange Book patents expired, were invalidated, or were successfully challenged. The practical launch date could also depend on:
- 30-month stays triggered by Paragraph IV litigation.
- Court-ordered launch restrictions.
- Settlement terms.
- At-risk launch decisions.
- FDA approval of the abbreviated new drug application.
- Commercial willingness to manufacture a complex delayed-release tablet.
Which companies have challenged or competed with Duexis?
Generic competition has come from companies capable of manufacturing complex oral dosage forms and defending formulation patents. Public litigation and ANDA activity have involved generic pharmaceutical manufacturers, including major U.S. and international suppliers.
The competitive set includes:
- Generic ibuprofen tablets combined with generic famotidine tablets.
- Generic ibuprofen combined with a proton-pump inhibitor.
- Prescription NSAIDs co-prescribed with omeprazole, pantoprazole, or another acid-suppressing product.
- COX-2 selective NSAIDs for patients in whom gastrointestinal risk is prioritized.
- OTC ibuprofen for lower-intensity pain.
The most direct substitute is not necessarily a generic fixed-dose product. Physicians can prescribe separate ibuprofen and famotidine at lower acquisition cost, although that approach adds pill burden and may reduce adherence.
How strong is the patent estate for ibuprofen and famotidine?
The patent estate is moderate in technical scope but weaker than a new-molecule estate because:
- Both active ingredients are long-established.
- The therapeutic concept is predictable.
- Acid suppression during NSAID treatment is clinically established.
- Separate-tablet substitution is straightforward.
- Formulation claims may be vulnerable to obviousness and anticipation challenges.
- A generic can potentially design around a particular release profile or dosage regimen.
The strongest practical protection is likely to reside in claims that combine the specific high-dose ibuprofen strength, famotidine dose, release characteristics, and dosing schedule. Broad claims covering any combination of ibuprofen and famotidine would face greater validity risk.
What manufacturing barriers affect generic entry?
Manufacturing barriers are meaningful but manageable. A generic company must demonstrate:
- Pharmaceutical equivalence.
- Bioequivalence for both active ingredients.
- Appropriate delayed-release characteristics.
- Stability across the commercial shelf life.
- Consistent famotidine and ibuprofen release.
- Control of impurities and degradation products.
- Compliance with current good manufacturing practices.
These requirements can delay approval, but they do not create the same barrier as sterile manufacturing, biologics comparability, or device-drug combination development.
What litigation and settlement issues affect generic launch?
Duexis generic litigation has centered on Orange Book-listed patents and ANDA applicants’ Paragraph IV certifications. The commercial consequences depend on whether a court finds the patents valid and infringed, whether the parties settle, and whether the settlement allows a licensed or authorized generic launch.
A settlement can preserve branded pricing longer than an adverse validity ruling. It can also create a defined generic entry date without establishing a broad legal precedent. The most important diligence items are:
| Diligence item |
Commercial impact |
| Paragraph IV filing date |
Establishes potential litigation trigger |
| 30-month stay |
Can delay FDA approval or commercial launch |
| Patent trial outcome |
Determines blocking strength |
| Authorized generic rights |
Can reduce first-filer economics |
| Settlement entry date |
Sets practical market opening |
| Exclusivity of first ANDA filer |
May affect generic concentration |
| At-risk launch |
Creates damages and injunction exposure |
A generic launch does not require every patent to be invalidated. It requires a legally available and commercially viable path around the remaining barriers.
What is the market size for ibuprofen and famotidine?
The addressable market is a narrow subset of the much larger global NSAID and gastroprotection markets. The product targets patients who need prescription-strength ibuprofen and have sufficient gastrointestinal risk to justify scheduled famotidine.
The market has three economic layers:
| Market layer |
Description |
Competitive pressure |
| Fixed-dose prescription product |
Duexis and any approved generic equivalent |
High from patent expiry and substitution |
| Separate prescription therapy |
Ibuprofen plus famotidine or a PPI |
High because of low cost |
| OTC and alternative NSAIDs |
Lower-dose ibuprofen, naproxen, celecoxib, and other therapies |
High across pain indications |
The commercial advantages are convenience, simplified prescribing, and a direct gastroprotection claim. The disadvantages are high price relative to separate generic components, a fixed ibuprofen dose, and the absence of protection from non-gastrointestinal NSAID risks.
Public financial disclosures have historically shown that Duexis generated meaningful revenue for its commercial owner, but the product’s sales are exposed to payer restrictions, specialty-pharmacy economics, generic substitution, and patent litigation. Standalone global market estimates are unreliable because many data vendors combine the product with the wider ibuprofen, NSAID, H2-blocker, or gastroprotection markets.
What is the sales projection for ibuprofen and famotidine?
A scenario-based projection is more defensible than a single point estimate because the principal variable is generic entry timing.
| Scenario |
2025-2026 |
2027-2028 |
2029-2030 |
Main assumption |
| Delayed generic entry |
Stable to modest decline |
5%-10% annual decline |
10%-15% annual decline |
Patent or settlement protection persists |
| One generic entrant |
20%-40% decline after launch |
40%-60% cumulative decline |
60%-75% cumulative decline |
Limited generic competition |
| Multiple generic entrants |
35%-60% decline after launch |
65%-85% cumulative decline |
80%-90% cumulative decline |
Rapid payer substitution and price erosion |
| Brand-only niche market |
Low single-digit annual decline |
Continued contraction |
Specialty-prescribing base remains |
No approved equivalent, but substitution continues |
These percentages represent branded revenue exposure, not total patient volume. A generic launch can increase unit utilization while sharply reducing brand revenue.
The fixed-dose product is most likely to retain value in patients who prioritize adherence, have stable insurance coverage, or are managed through channels where substitution is limited. Revenue risk is highest if the FDA approves an AB-rated generic that matches the delayed-release product and multiple suppliers enter within a short period.
How does ibuprofen and famotidine compare with separate ibuprofen and proton-pump inhibitor therapy?
| Factor |
Ibuprofen/famotidine |
Ibuprofen plus PPI |
| Pill burden |
Lower |
Higher |
| Acquisition cost |
Usually higher |
Usually lower |
| Evidence base |
Supports endoscopic ulcer reduction |
Broad evidence for NSAID gastroprotection |
| Dosing flexibility |
Limited by fixed tablet |
High |
| High-risk ulcer prevention |
May be insufficient for some patients |
Often preferred in high-risk patients |
| Cardiovascular NSAID risk |
Remains |
Remains |
| Adherence |
Potentially improved |
Depends on patient behavior |
| Generic substitution |
Depends on complex formulation |
Widely available |
For patients with prior ulcer bleeding, concurrent anticoagulant use, advanced age, or multiple gastrointestinal risk factors, clinicians may prefer a proton-pump inhibitor strategy based on guideline recommendations and patient-specific risk. The combination does not eliminate the need to select the lowest effective NSAID dose for the shortest duration.
What generic launch risks exist?
The main generic launch risks are commercial and legal rather than clinical.
High-probability risks
- Price erosion following an AB-rated generic launch.
- Payer substitution away from Duexis.
- Authorized-generic competition.
- Generic design-around using separate tablets.
- Formulation patent invalidity.
- Limited differentiation after patent expiry.
- Prescription migration to ibuprofen plus a PPI.
Moderate-probability risks
- Delayed generic launch because of manufacturing complexity.
- Concentrated supply from one or two approved manufacturers.
- Continued brand use in specialty or adherence-sensitive patients.
- Settlement-based entry that delays but does not prevent competition.
Biosimilar risk is not relevant. Duexis is a small-molecule oral product, not a biologic. The relevant regulatory pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under section 351(k).
What licensing deals affect ibuprofen and famotidine?
The product originated from Pozen’s proprietary combination technology and was commercialized through Horizon Pharma. Horizon later became part of Amgen through Amgen’s acquisition of Horizon in 2023.[5]
The principal licensing and corporate-development relevance is therefore historical ownership and commercialization rights rather than an active biologic-style licensing network. Any current transaction analysis should distinguish:
- Product ownership.
- U.S. commercialization rights.
- Manufacturing rights.
- Authorized-generic rights.
- Litigation settlements.
- Distribution agreements.
- Post-acquisition portfolio ownership.
What geographic markets are most relevant?
The United States is the principal market for Duexis. The product’s commercial profile is less transferable internationally because:
- Brand and patent status differ by country.
- Famotidine and ibuprofen availability varies.
- Many markets favor separate low-cost generic products.
- NSAID prescribing guidelines differ.
- Fixed-dose combinations may face different reimbursement rules.
- Regulatory approval for the exact delayed-release formulation is jurisdiction-specific.
European and other international markets are more likely to use separate NSAID and gastroprotective prescriptions unless a locally approved equivalent has established reimbursement.
Key Takeaways
- Duexis is a prescription fixed-dose combination of ibuprofen 800 mg and famotidine 26.6 mg.
- FDA approval dates to April 28, 2011, under NDA 022519.
- REDUCE-1 and REDUCE-2 demonstrated lower endoscopic ulcer rates than ibuprofen alone.
- The clinical program did not establish lower cardiovascular risk or superiority over proton-pump inhibitor-based gastroprotection.
- The commercial patent estate is formulation- and method-based, not compound-based.
- Generic risk is high because ibuprofen and famotidine are both off-patent active ingredients.
- Biosimilar competition does not apply.
- The principal market substitutes are separate ibuprofen plus famotidine, ibuprofen plus a PPI, and alternative NSAIDs.
- Branded revenue could decline 60%-90% after multiple generic entrants, depending on substitution speed and settlement terms.
- The product’s remaining value is concentrated in adherence, convenience, payer access, and any enforceable formulation protection.
Frequently Asked Questions
Is Duexis safer than ibuprofen alone?
Duexis reduces endoscopic ulcer formation compared with ibuprofen alone, but it retains the cardiovascular, renal, blood-pressure, and serious gastrointestinal risks associated with high-dose ibuprofen.[1]
Can famotidine replace a proton-pump inhibitor for NSAID protection?
Famotidine provides acid suppression, but a proton-pump inhibitor may be preferred for patients with high gastrointestinal risk or prior ulcer bleeding. Treatment should reflect the patient’s NSAID exposure and risk factors.
Is there a generic for Duexis?
Generic availability depends on FDA approval, Orange Book patent status, litigation, and commercial launch. A generic must demonstrate equivalence to the fixed-dose delayed-release product or use another legally permitted approval strategy.
Does Duexis prevent gastrointestinal bleeding?
The pivotal evidence primarily demonstrated a reduction in endoscopic ulcers. It did not establish definitive prevention of all gastrointestinal bleeding, perforation, or hospitalization events.
Why is a fixed-dose ibuprofen/famotidine tablet more expensive than separate generic drugs?
The fixed product incorporates formulation technology, prescription-brand economics, distribution costs, and historical patent protection. Separate generic ibuprofen and famotidine are generally less expensive but increase pill burden and reduce dosing flexibility.
References
-
U.S. Food and Drug Administration. (2023). Duexis (ibuprofen and famotidine) prescribing information. FDA.
-
Laine, L., Kivitz, A. J., Bello, A. E., Grahn, A. Y., Schiff, M. H., & Targownik, L. E. (2012). Validation of a disease-specific symptom measure for osteoarthritis of the knee. The American Journal of Gastroenterology, 107(Suppl. 1).
-
National Library of Medicine. (n.d.). ClinicalTrials.gov: Ibuprofen and famotidine studies. ClinicalTrials.gov.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Amgen Inc. (2023). Amgen completes acquisition of Horizon Therapeutics plc. Amgen investor relations.
